Medical Network January 16th, January 15th, AstraZeneca announced that guanylate cyclase agonist Ze Ze (linaclotide) officially approved for listing in China. As a prescription drug for the treatment of adult constipation-type irritable bowel syndrome (IBS-C) in China, the approval of Zeshu will fill the treatment gap of adult constipation-type irritable bowel syndrome in China, and bring the gospel to the majority of domestic patients.
Linaclotide has been approved for marketing in more than 30 countries around the world for the treatment of constipation-type irritable bowel syndrome. AstraZeneca and Ironwood Pharmaceutical Co., Ltd. reached a cooperation in 2012, jointly responsible for the development and listing of Zeshu in China.
It is understood that constipation-type irritable bowel syndrome (IBS-C) is a recurrent episode, which is the main feature of functional bowel disease with abdominal pain, bloating and abdominal discomfort, which seriously affects the quality of work and life. Ze Zeshu's innovative mechanism is to activate the body's own guanylate cyclase to promote intestinal secretion, and to reduce the visceral hypersensitivity, to relieve abdominal pain, bloating and constipation in patients with constipation-type irritable bowel syndrome. The effect of the symptoms.
Chinese Medical Association credits will digest chairman of disease, vice president Professor Chen Min, First Affiliated Hospital of Sun Yat Lake said: "constipation-predominant irritable bowel syndrome is a disease affecting the quality of life, current treatments are very limited linaclotide. the peptide was approved for marketing, provide a new option for the treatment of patients with irritable bowel syndrome, will also promote constipation-predominant irritable bowel syndrome move to standardization, standardization, to improve the diagnosis and treatment of constipation-predominant irritable bowel syndrome It has important significance."
Professor Tang Chengwei, the deputy director of the Chinese Medical Association Digestive Diseases Branch and director of the Department of Gastroenterology, West China Hospital of Sichuan University, said: "Linaglutide is the first guanylate cyclase agonist approved in mainland China. The listing will provide better treatment options for patients with constipation-type irritable bowel syndrome in China, and help patients improve their symptoms and improve their quality of life from a new perspective."
Chen Zhijian, senior vice president of global drug development at AstraZeneca and president of China New Drug Development Department, said: "AstraZeneca China New Drug Development Department has always been 'patient-centered' and is committed to discovering and meeting the most pressing treatment needs of Chinese patients. The approval will bring groundbreaking treatments for patients with constipation-type irritable bowel syndrome in China."
"As an innovative prescription drug for the treatment of constipation-type irritable bowel syndrome, Zeshu has filled the treatment gap in China." Alibaba's global executive vice president, international business and China president Wang Lei said: "In the future, AstraZeneca still It is our responsibility to introduce global innovative drugs into China. At the same time, we work together with professional associations, physicians and partners in the field of digestive fields to improve the accessibility of drugs and enable Chinese patients to enjoy the treatment of new international drugs in the first place."
Greenhouse Sun-Shading System can reduce solar load, and cool down the inside temperature and create a comfortable environment for the plants.
Greenhouse Sun-Shading System,Greenhouse Shade Netting,Greenhouse Shade Cloth,Greenhouse Shading